Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat vs Darbepoetin alfa in Anemia of NDD CKD
NCT02021318Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of roxadustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy. Started Mar 2014; status: completed.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02021318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021318.